Sort   by:  
 Page size 
UnknownKeynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer.
Not available
S-EPMC7791256 | biostudies-literature
UnknownParadigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Not available
S-EPMC8197177 | biostudies-literature
UnknownHDAC Inhibition to Prime Immune Checkpoint Inhibitors.
Not available
S-EPMC8750966 | biostudies-literature
UnknownMOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer.
Not available
S-EPMC12639439 | biostudies-literature
UnknownTremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.
Not available
S-EPMC12359660 | biostudies-literature
UnknownClinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma.
Not available
S-EPMC7049986 | biostudies-literature
UnknownDurvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.
Not available
S-EPMC11749830 | biostudies-literature
UnknownPrevious treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study.
Not available
S-EPMC11763860 | biostudies-literature
UnknownDissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy.
Not available
S-EPMC8602606 | biostudies-literature
UnknownHyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.
Not available
S-EPMC6896059 | biostudies-literature
Sort   by:  
 Page size